New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s Disease

 

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimer’s in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimer’s disease medications are giving new options to patients.

“Alzheimer’s research is getting to a place where cancer research was maybe 30, 40 years ago,” says Anton Porsteinsson, MD, director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. “I think we’re at a point where we’re going to see a logarithmic increase in discovery.”

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dung’s Thoughts

“Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimer’s disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinson’s disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best we’ve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently. ”

Article written by Sonya Young.

Follow us on social media for the latest updates in B2B!

Image

Latest

Leadership
How the Future of Work Is Being Reshaped by AI, Human Creativity, and Customer-Centered Leadership
May 21, 2026

As artificial intelligence rapidly reshapes industries, many professionals are asking the same urgent question: what happens when AI starts replacing not just repetitive tasks, but the foundational entry-level roles that once launched careers? According to Goldman Sachs Research, AI could expose the equivalent of 300 million jobs globally to automation, while potentially automating tasks…

Read More
finance
Dr. Silver Kung’s Path From $10 Million in Debt to a Multibillion-Dollar Finance Career
May 21, 2026

Global finance is being tested by forces that no balance sheet can fully predict: unstable supply chains, geopolitical shocks, tighter credit conditions and the accelerating rise of AI. In trade finance especially, success depends on more than capital; it requires judgment, discipline and the ability to see risk before it becomes disruption. As automation…

Read More
specialty pharmacy
At the Center of Care: How Specialty Pharmacy Aligns Patients, Providers, and Payers
May 21, 2026

As healthcare costs continue to rise, more patients are finding themselves navigating not just illness, but the growing complexity of paying for treatment. Specialty pharmacy sits right at the center of that challenge—often out of sight, but increasingly essential to how modern care actually works. These high-cost, high-touch therapies now make up more than…

Read More
Language development
Just Thinking… About How Multilingualism and Language Development Belong at the Center of Student Learning
May 20, 2026

For millions of students in America, learning English is only one part of a much larger academic story. A 2024 GAO report found that English learners in U.S. public schools grew from 4.5 million to 5 million students between fall 2010 and fall 2020, and that they speak more than 400 languages. That diversity…

Read More